JVM Co

JVM Co CapEx/D&A

The CapEx to Depreciation Ratio of JVM Co (054950.KQ) as of Nov 4, 2026 is 1.83. In the previous year, CapEx to Depreciation Ratio was 1.68 — a change of 8.97% (higher).

CapEx/D&A

1.83

YoY

8.97%

Last updated:

CapEx to Depreciation Ratio of JVM Co is 2024 1.83 . CapEx to Depreciation Ratio of JVM Co was 2023 1.68 . It decreases by 8.97% higher compared to the previous year.

The JVM Co CapEx/D&A history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/D&A
Date
CapEx/D&A
Jan 1, 2017
3.20 KRW
Jan 1, 2018
2.70 KRW
Jan 1, 2019
2.12 KRW
Jan 1, 2020
4.39 KRW
Jan 1, 2021
2.75 KRW
Jan 1, 2022
2.35 KRW
Jan 1, 2023
1.68 KRW
Jan 1, 2024
1.83 KRW
The JVM Co CapEx/D&A history
YEARCapEx/D&AYoY
1.83+8.97%
1.68-28.48%
2.35-14.37%
2.75-37.40%
4.39+106.53%
2.12-21.34%
2.70-15.48%
3.20-7.74%
3.46+14.89%
3.02+27.82%
2.36—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

JVM Co Stock analysis

What does JVM Co do? JVM Co., Ltd. manufactures pharmacy automation systems under the brand JVM, targeting domestic and overseas markets. The company's primary products include automatic tablet dispensing and packaging systems (ATDPSs), automatic tablet classification and packing machines available in slide, box, and drum types, total safety solutions, automatic medication vision inspection systems (VIZENs), automatic package cutting and winding systems (WIZERs), and automatic medication sorting and control systems (AccuPharm). These products are sold to customers in the pharmaceutical and healthcare sectors seeking efficient automation solutions for medication handling and safety. The firm generates revenue through the sale of its branded automation systems, with a focus on domestic distribution and international markets. JVM's product portfolio addresses key operational needs in pharmacy settings, including dispensing, classification, inspection, and sorting of medications, ensuring compliance with safety standards while improving workflow efficiency. The company's offerings are designed to meet the demands of healthcare providers and pharmaceutical manufacturers requiring advanced automation technologies. JVM's business model centers on providing comprehensive automation solutions for pharmacy operations, leveraging its established brand JVM to differentiate its products in the market. By offering a wide range of specialized systems, the company caters to both domestic and international clients seeking reliable, high-quality automation equipment for medication management and safety protocols. JVM Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about JVM Co stock

CapEx to Depreciation Ratio of JVM Co is 1.83 in 2024.

CapEx to Depreciation Ratio of JVM Co changed from 1.68 to 1.83, representing a 8.97% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Depreciation Ratio JVM Co since 2006 – with annual values, charts, and detailed analysis.

The CapEx/D&A ratio compares investment spending to asset depreciation. Ratios above 1.0x indicate the company is growing its asset base, below 1.0x suggests underinvestment.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Depreciation Ratio's JVM Co with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Depreciation Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Depreciation Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — JVM Co

All Key Metrics — JVM Co